EE200200213A - Suukaudselt manustatav galantamiinilahus - Google Patents

Suukaudselt manustatav galantamiinilahus

Info

Publication number
EE200200213A
EE200200213A EEP200200213A EEP200200213A EE200200213A EE 200200213 A EE200200213 A EE 200200213A EE P200200213 A EEP200200213 A EE P200200213A EE P200200213 A EEP200200213 A EE P200200213A EE 200200213 A EE200200213 A EE 200200213A
Authority
EE
Estonia
Prior art keywords
solution
galantamine
oral
oral galantamine
galantamine solution
Prior art date
Application number
EEP200200213A
Other languages
English (en)
Inventor
Karel Jozef Fran�ois Marc
Mathilde Jozef Kempen Tony
Andr� Jos�e De Proost Eddy
Original Assignee
Janssen Pharmaceutica N.V.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Janssen Pharmaceutica N.V. filed Critical Janssen Pharmaceutica N.V.
Publication of EE200200213A publication Critical patent/EE200200213A/et
Publication of EE05230B1 publication Critical patent/EE05230B1/et

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0087—Galenical forms not covered by A61K9/02 - A61K9/7023
    • A61K9/0095—Drinks; Beverages; Syrups; Compositions for reconstitution thereof, e.g. powders or tablets to be dispersed in a glass of water; Veterinary drenches
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/32—Alcohol-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/22—Heterocyclic compounds, e.g. ascorbic acid, tocopherol or pyrrolidones

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biomedical Technology (AREA)
  • Psychiatry (AREA)
  • Epidemiology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Addiction (AREA)
  • Psychology (AREA)
  • Immunology (AREA)
  • Rheumatology (AREA)
  • Hospice & Palliative Care (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Saccharide Compounds (AREA)
  • Coloring Foods And Improving Nutritive Qualities (AREA)
EEP200200213A 1999-10-26 2000-10-16 Suukaudselt manustatav galantamiinilahus ja meetod selle valmistamiseks EE05230B1 (et)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP99203512 1999-10-26
PCT/EP2000/010203 WO2001030318A1 (en) 1999-10-26 2000-10-16 Oral solution containing galanthamine and a sweetening agent

Publications (2)

Publication Number Publication Date
EE200200213A true EE200200213A (et) 2003-06-16
EE05230B1 EE05230B1 (et) 2009-12-15

Family

ID=8240778

Family Applications (1)

Application Number Title Priority Date Filing Date
EEP200200213A EE05230B1 (et) 1999-10-26 2000-10-16 Suukaudselt manustatav galantamiinilahus ja meetod selle valmistamiseks

Country Status (29)

Country Link
EP (1) EP1237539B1 (et)
JP (1) JP2003512415A (et)
KR (1) KR100502391B1 (et)
CN (1) CN1200691C (et)
AR (1) AR026243A1 (et)
AT (1) ATE306904T1 (et)
AU (1) AU780826C (et)
BG (1) BG65792B1 (et)
BR (1) BR0015025A (et)
CA (1) CA2388830C (et)
CZ (1) CZ301996B6 (et)
DE (1) DE60023341T2 (et)
DK (1) DK1237539T3 (et)
EA (1) EA005683B1 (et)
EE (1) EE05230B1 (et)
ES (1) ES2250211T3 (et)
HR (1) HRP20020332B1 (et)
HU (1) HUP0203484A3 (et)
IL (2) IL149310A0 (et)
IS (1) IS2628B (et)
MX (1) MXPA02004149A (et)
NO (1) NO332096B1 (et)
PL (1) PL201694B1 (et)
SI (1) SI1237539T1 (et)
SK (1) SK285643B6 (et)
TW (1) TW592725B (et)
UA (1) UA76095C2 (et)
WO (1) WO2001030318A1 (et)
ZA (1) ZA200203313B (et)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20030162770A1 (en) * 2002-02-22 2003-08-28 Davis Bonnie M. Use of modulators of nicotinic receptors for treatment of cognitive dysfunction
US7297691B2 (en) 2003-08-13 2007-11-20 Janssen Pharmaceutica N.V. Treatment of sleep disorders with cholinesterase inhibitors
US20050191349A1 (en) * 2003-12-31 2005-09-01 Garth Boehm Galantamine formulations
US8709521B2 (en) * 2007-05-22 2014-04-29 The Coca-Cola Company Sweetener compositions having enhanced sweetness and improved temporal and/or flavor profiles
US9708366B2 (en) * 2011-01-27 2017-07-18 Neuren Pharmaceuticals Ltd. Treatment of fragile X syndrome using glycyl-L-2-methylprolyl-L-glutamate
WO2014059363A1 (en) * 2012-10-11 2014-04-17 Antrim Pharmaceuticals Llc Oral solution formulations of aripiprazole
JP6457582B2 (ja) * 2017-04-14 2019-01-23 エルメッド エーザイ株式会社 ガランタミン含有医薬組成物、並びに医薬組成物におけるガランタミンの苦味抑制方法、及びガランタミンの苦味抑制剤
CN117717558A (zh) * 2023-12-06 2024-03-19 艾威药业(珠海)有限公司 加兰他敏及其药学上可接受的盐在制备治疗眼部疾病的药物中的应用

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE4010079A1 (de) * 1990-03-29 1991-10-02 Lohmann Therapie Syst Lts Pharmazeutische formulierung zur behandlung des alkoholismus
US5272137A (en) * 1992-02-14 1993-12-21 Mcneil-Pfc, Inc. Aqueous pharmaceutical suspension for pharmaceutical actives
US6323195B1 (en) * 1993-10-15 2001-11-27 Aventis Pharmaceuticals Inc. Galanthamine derivatives as acetylcholinesterase inhibitors
JPH10273435A (ja) * 1997-01-29 1998-10-13 Fujisawa Pharmaceut Co Ltd 内服用液剤

Also Published As

Publication number Publication date
UA76095C2 (en) 2006-07-17
JP2003512415A (ja) 2003-04-02
MXPA02004149A (es) 2002-10-17
DE60023341T2 (de) 2006-07-27
BG106534A (en) 2002-12-29
KR20020026010A (ko) 2002-04-04
ATE306904T1 (de) 2005-11-15
CA2388830A1 (en) 2001-05-03
CN1382037A (zh) 2002-11-27
SI1237539T1 (sl) 2006-04-30
CZ301996B6 (cs) 2010-09-01
AR026243A1 (es) 2003-02-05
IS2628B (is) 2010-05-15
DE60023341D1 (de) 2006-03-02
EA200200486A1 (ru) 2002-10-31
NO332096B1 (no) 2012-06-18
IL149310A0 (en) 2002-11-10
HUP0203484A3 (en) 2004-12-28
NO20022003L (no) 2002-06-18
ZA200203313B (en) 2003-11-26
ES2250211T3 (es) 2006-04-16
CZ20021329A3 (cs) 2002-08-14
EE05230B1 (et) 2009-12-15
CN1200691C (zh) 2005-05-11
DK1237539T3 (da) 2006-02-27
BR0015025A (pt) 2002-06-18
CA2388830C (en) 2006-09-19
HUP0203484A2 (hu) 2003-02-28
PL362849A1 (en) 2004-11-02
EP1237539B1 (en) 2005-10-19
WO2001030318A1 (en) 2001-05-03
HRP20020332B1 (hr) 2011-02-28
IL149310A (en) 2006-12-10
EA005683B1 (ru) 2005-04-28
AU1384901A (en) 2001-05-08
EP1237539A1 (en) 2002-09-11
KR100502391B1 (ko) 2005-07-19
NO20022003D0 (no) 2002-04-26
SK5302002A3 (en) 2002-10-08
IS6291A (is) 2002-02-28
AU780826C (en) 2006-02-16
BG65792B1 (bg) 2009-12-31
PL201694B1 (pl) 2009-04-30
AU780826B2 (en) 2005-04-21
SK285643B6 (sk) 2007-05-03
TW592725B (en) 2004-06-21
HK1049619A1 (en) 2003-05-23
HRP20020332A2 (en) 2004-02-29

Similar Documents

Publication Publication Date Title
IS2116B (is) 4-fenyl-pyridin afleiður
DE50010060D1 (de) Thiazolylamid-derivate
ATE263748T1 (de) Admantan-derivate
EE200100613A (et) 13-metüülerütromütsiini derivaadid
DE60007530D1 (de) Oral wirksame androgene
EE200200150A (et) Preparaat
ATA111299A (de) Schnullersauger
DK1187814T3 (da) 5-phenyl-pyrimidinderivater
ATE270270T1 (de) Neuartige phenylalkyloxy-phenyl-derivate
ATE257148T1 (de) Propargyletherderivate
IS6398A (is) Lyfjablöndur
DE60043058D1 (de) Dentalwerkstoffe
DK1154988T3 (da) Mevinolinderivater
ATE374747T1 (de) Monofluoralkylderivate
ATE293592T1 (de) Resorcinderivate
DK1218340T3 (da) 4-hydroxybiphenylhydrazid-derivater
DK1187815T3 (da) 4-phenyl-pyrimidinderivater
DE50015795D1 (de) Sektionaltor
ID30397A (id) Larutan oral prukaloprida
EE200200213A (et) Suukaudselt manustatav galantamiinilahus
DE60025348D1 (de) Ethansulfonyl-piperidin-derivate
DK1178984T3 (da) 1-trifluormethyl-4-hydroxy-7-piperidinylaminomethylchroman-derivater
DE59909774D1 (de) 1-cycloalkylpyrazolyl-benzoyl-derivate
DE60020365D1 (de) Säurekatalysierte umsetzungen
NO991585D0 (no) Trekkanordning

Legal Events

Date Code Title Description
KB4A Valid patent at the end of a year

Effective date: 20101231